INZY – inozyme pharma, inc. (US:NASDAQ)
Stock Stats
News
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Bank of America Co. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency [Yahoo! Finance]
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Form ARS Inozyme Pharma, Inc. For: Dec 31
Form DEFA14A Inozyme Pharma, Inc.
Form DEF 14A Inozyme Pharma, Inc. For: Jun 18
Form 8-K Inozyme Pharma, Inc. For: Apr 08
Form 4 Inozyme Pharma, Inc. For: Mar 28 Filed by: Winton Matthew
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.